Novartis expects China growth to recover; Pfizer reaches deal on Quigley asbestos claims;

@FiercePharma: Regulatory headwinds scuttle Sanofi, Merck JV. News | Follow @FiercePharma

> Novartis expects growth in China to recover after business restructuring in the country slowed the Swiss drug giant's sales there last year, Chief Executive Joe Jimenez said. Report

> Pfizer reached a $263 million-plus settlement with asbestos claimants that may bring an end to its Quigley unit's seven-year-old bankruptcy case. News

> Expanding its presence in the Chinese vaccines market, Novartis said it acquired an 85 percent stake in the Chinese vaccines company Zhejiang Tianyuan Bio-Pharmaceutical. Article

> The U.K.'s cost-effectiveness watchdog issued final guidance recommending Celgene's Vidaza drug as a treatment option for people with myelodysplastic syndromes. NICE release

> Aurobindo Pharma says it has received final approval from FDA to market famciclovir tablets, the generic version of Novartis' Famvir, used for treating herpes simplex infections in HIV-infected patients. News

> Glenmark Pharmaceuticals won final FDA approval to market its generic oral contraceptive drug Breillyn. Story

> One of Japan's largest over-the-counter drug makers, Sato Pharmaceutical, reports that there were no injuries to its employees nor damages to its many factories in Japan due to the earthquake and tsunami. Item

Biotech News

@FierceBiotech: Labopharm slashes staff, pushes strategic review. News  | Follow @FierceBiotech

@JohnCFierce: Looks like Peptimmune is heading off into the sunset. Article | Follow @JohnCFierce

> Which are the best dealmakers in the biopharma business? News

> Gilead's HIV drug aces Ph3 comparison test with Isentress. Article 

> Xoma shares blitzed after lead drug flunks key diabetes study. Story 

> Fresh delay for Novartis's indacaterol app. News

> Accenture: "Radical" informatics change required to reshape R&D ops. Report 

Drug Delivery News

> Tekmira sues RNAi drug-delivery partner Alnylam. Report 

> Puzzle solved to deliver RNA drugs into brain. News

> MRI guides cancer drug directly to liver. Story 

> Startup with "spidersilk" for drug delivery raises $7M. Item 

> OncoSec, cancer drug delivery firm, taking form. Article 

> More cancer-killing gold found in gold nanoparticles? Story

Medical Device News

> ACT study aims to demonstrate safety, efficacy of TEMPASURE catheter. News

> Ex-Exactech rep to pay $56K for role in kickback scheme. Story

> Terumo unit enters consent decree, gives up $35M in profits. Article

> St. Jude shares up on JP Morgan analyst note. Report 

> ReGen says it's fed up with FDA's 'agenda,' refuses hearing. News

> Nordion to evaluate TheraSphere in PhIII. Story

> Core Essence raises $11.5M in Series B funding. Article

And Finally... With psychiatrists and even primary care doctors scarce in some areas, states may let psychologists prescribe psychotropic drugs. Report

Suggested Articles

Seattle Genetics and Astellas’ newcomer Padcev now has what every cancer drugmaker is looking for: Randomized trial data showing it can extend lives.

A patent decision in Delaware clears the way for multiple generic companies to launch their Tecfidera copycats—and target its $3.3B in U.S. sales.

Sanofi and GlaxoSmithKline signed a deal with the EU to supply up to 300 million doses of their recombinant protein-based COVID-19 vaccine.